Vera Therapeutics, Inc. (NASDAQ:VERA) Stock Has Average Target Price of $76.86 According to Analysts

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have been given an average recommendation of “Moderate Buy” by the fifteen analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $74.93.

A number of brokerages have commented on VERA. JPMorgan Chase & Co. increased their price objective on Vera Therapeutics from $76.00 to $83.00 and gave the company an “overweight” rating in a research report on Tuesday, September 8th. Guggenheim cut their price objective on shares of Vera Therapeutics from $76.00 to $66.00 and set a “buy” rating for the company in a research report on Friday. HC Wainwright cut their price objective on Vera Therapeutics from $90.00 to $75.00 and set a “buy” rating for the company in a report on Friday. Leerink Partners began coverage on shares of Vera Therapeutics in a report on Monday, October 12th. They set a “market perform” rating and a $34.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vera Therapeutics in a research report on Friday, October 23rd.

Key Vera Therapeutics News

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: For Q3 2026, Vera reported a loss of $1.30 per share, narrower than the $1.62 consensus loss, and revenue of $10.28 million versus estimates of $3.42 million. The earnings beats are supportive, although the company remained loss-making. Quarterly earnings report
• Positive Sentiment: HC Wainwright cut its price target to $75 from $90 but maintained a Buy rating. Its revised target still implies substantial upside from the cited $29.79 share price, which may offer support to investors. HC Wainwright rating update
• Neutral Sentiment: Vera granted stock options covering 14,900 shares and restricted stock units covering 7,450 shares to three new employees. The awards are a routine hiring incentive, with a small potential dilution effect. Inducement grants announcement
• Negative Sentiment: A valuation-focused article argues VERA may be above fair value after a 148% run, raising the risk that investors take profits or demand stronger progress to justify the share price. Valuation analysis
• Negative Sentiment: Although HC Wainwright remains bullish, its $15 reduction in the target reflects a more cautious view than before and may temper optimism. HC Wainwright rating update

Insider Activity

In other news, CEO Marshall Fordyce sold 18,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $37.00, for a total transaction of $684,500.00. Following the sale, the chief executive officer directly owned 235,244 shares in the company, valued at approximately $8,704,028. The trade was a 7.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Pictet Asset Management Holding SA raised its position in Vera Therapeutics by 47.2% in the third quarter. Pictet Asset Management Holding SA now owns 1,839,245 shares of the company’s stock valued at $59,397,000 after purchasing an additional 589,831 shares during the period. Readystate Asset Management LP bought a new position in Vera Therapeutics in the 2nd quarter valued at approximately $12,663,000. Renaissance Technologies LLC boosted its holdings in Vera Therapeutics by 136.5% in the 1st quarter. Renaissance Technologies LLC now owns 457,300 shares of the company’s stock valued at $18,397,000 after purchasing an additional 263,900 shares during the period. Engineers Gate Manager LP lifted its position in Vera Therapeutics by 1,579.2% during the second quarter. Engineers Gate Manager LP now owns 108,139 shares of the company’s stock valued at $4,640,000 after purchasing an additional 101,699 shares during the period. Finally, Candriam S.C.A. grew its stake in Vera Therapeutics by 21.5% in the 3rd quarter. Candriam S.C.A. now owns 568,560 shares of the company’s stock worth $18,426,000 after acquiring an additional 100,461 shares in the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Trading Down 1.2%

VERA stock opened at $29.78 on Monday. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.92. The company has a fifty day moving average price of $31.60 and a two-hundred day moving average price of $36.68. The stock has a market cap of $2.15 billion, a price-to-earnings ratio of -5.05 and a beta of 1.07. Vera Therapeutics has a one year low of $23.86 and a one year high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.62) by $0.32. The company had revenue of $10.28 million for the quarter, compared to the consensus estimate of $3.42 million. Equities analysts anticipate that Vera Therapeutics will post -6.45 EPS for the current year.

About Vera Therapeutics

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. The company’s research is centered on therapies that target the underlying causes of autoimmune conditions rather than primarily addressing their symptoms.

Vera’s lead product candidate is atacicept, a biologic designed to inhibit the B-cell survival factors BLyS and APRIL. The company has been evaluating atacicept in IgA nephropathy, an autoimmune kidney disease that can lead to progressive loss of kidney function, and has also investigated its potential in other immune-mediated diseases.